aibioIONS Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals (IONS) news
Top story · Oct 23, 2026 · SEC filing 8-K
Ionis Pharmaceuticals files a company update
On October 23, 2026, Ionis’ partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgAN receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P The treatment effect
Latest Ionis Pharmaceuticals news
We have not published a story on Ionis Pharmaceuticals yet. When there is news, it will appear here.
Ionis Pharmaceuticals annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $915.6 million | $901.5 million |
| Net income (loss) | -$381.4 million | -$453.9 million |
| Cash from operations | -$268.6 million | -$500.9 million |
| Cash and equivalents | $372.3 million | $242.1 million |
| Short-term investments | $2.31 billion | $2.06 billion |
Questions about Ionis Pharmaceuticals
What is the ticker symbol of Ionis Pharmaceuticals?
Ionis Pharmaceuticals, Inc. trades under the ticker IONS on NASDAQ.
Where is Ionis Pharmaceuticals listed?
Ionis Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:ISI; FWB:ISI; GETTEX:ISI; HAM:ISI; HAN:ISI; LS:A2ACMZ; LSE:0JDI; LSX:A2ACMZ; MUN:ISI; SWB:ISI; TRADEGATE:ISI; XETR:ISI.
What is the SEC CIK of Ionis Pharmaceuticals?
The SEC Central Index Key (CIK) for Ionis Pharmaceuticals, Inc. is 874015. Its filings are on SEC EDGAR.
How many shares does Ionis Pharmaceuticals have outstanding?
166,184,322 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-29.
Which country or territory is Ionis Pharmaceuticals listed under?
Our directory records Ionis Pharmaceuticals, Inc. under United States.
What does Ionis Pharmaceuticals do?
Our directory classifies Ionis Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Ionis Pharmaceuticals?
The ISIN recorded for Ionis Pharmaceuticals, Inc. is US4622221004.
Does aibio.space cover Ionis Pharmaceuticals?
aibio.space lists Ionis Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Ionis Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as CA.
Is Ionis Pharmaceuticals profitable?
Ionis Pharmaceuticals, Inc. reported a net loss of $381.4 million for the fiscal year ended Dec 31, 2025, and used $268.6 million of cash in operations, per its annual report to the SEC.
How much does Ionis Pharmaceuticals spend on research and development?
$915.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Ionis Pharmaceuticals have?
$2.05 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is Ionis Pharmaceuticals's market cap?
We do not publish live share prices. In its annual report, Ionis Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $5.28 billion as of Jun 30, 2025.
Is Ionis Pharmaceuticals a smaller reporting company?
SEC records list Ionis Pharmaceuticals, Inc.'s filer category as: Large accelerated filer.
Where is Ionis Pharmaceuticals headquartered?
SEC records list its business address as 2855 GAZELLE COURT, CARLSBAD, CA, 92010.
Investor discussion: Ionis Pharmaceuticals
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Ionis Pharmaceuticals Inc
- CIK
- 874015
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- IONS (Nasdaq)
- State or country of incorporation
- CA
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 2855 GAZELLE COURT, CARLSBAD, CA, 92010
- Phone
- 7609319200
- Shares outstanding
- 166,184,322 as of 2026-07-23 (10-Q filed 2026-07-29)
- Former names
- ISIS PHARMACEUTICALS INC
Recent filings
Listing details
- Company
- Ionis Pharmaceuticals, Inc.
- Ticker
- IONS
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US4622221004
- Other listed symbols
- DUS:ISI; FWB:ISI; GETTEX:ISI; HAM:ISI; HAN:ISI; LS:A2ACMZ; LSE:0JDI; LSX:A2ACMZ; MUN:ISI; SWB:ISI; TRADEGATE:ISI; XETR:ISI
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction